Group
VEGF-trap
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Anti-VEGF |
| Mechanism of Action | VEGF-trap |
| Drugs in group | Aflibercept |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing via vascular normalization (↓hypoxia, ↓RT-induced VEGF/edema) (Subudhi et al., Cell, 2026; Kanthou and Tozer, British Journal of Radiology, 2019). As a VEGF-pathway agent, the same non-selective endothelial effect provides a rationale for increased vascular normal-tissue adverse events (GI perforation/fistula, impaired healing, possible radionecrosis) analogous to bevacizumab.
The data above refer to patients treated with VEGF-trap as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.